Functional analysis of UGT1A4 P24T and UGT1A4 L48V variant enzymes

Pharmacogenomics

Volumn 12, Issue 12, 2011, Pages 1671-1679

  Zhou, Jin ^a   Argikar, Upendra A ^b   Remmel, Rory P ^c  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

dihydrotestosterone; enzyme kinetic; glucuronidation; heteroactivation; lamotrigine; polymorphism; tamoxifen; transandrosterone; UGT1A4

Indexed keywords

ANDROSTANOLONE; ANDROSTERONE DERIVATIVE; GLUCURONOSYLTRANSFERASE 1A4; LAMOTRIGINE; RECOMBINANT ENZYME; TAMOXIFEN; TRANSANDROSTERONE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME KINETICS; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

DIHYDROTESTOSTERONE; GENE EXPRESSION; GLUCURONOSYLTRANSFERASE; HEK293 CELLS; HUMANS; ISOENZYMES; POLYMORPHISM, SINGLE NUCLEOTIDE; TAMOXIFEN; TRIAZINES;

EID: 82255193120     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.105     Document Type: Article

References (23)

1. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 3 (3), 136-158 (2003). (Pubitemid 36850156)
2. Strassburg CP. Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics 9 (6), 703-715 (2008).
3. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91 (4), 678-682 (2004). (Pubitemid 39141623)
4. Onoue M, Terada T, Kobayashi M et al. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int. J. Clin. Oncol. 14 (2), 136-142 (2009).
5. Ehmer U, Vogel A, Schutte JK, Krone B, Manns MP, Strassburg CP. Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 39 (4), 970-977 (2004). (Pubitemid 38428936)
6. Wiener D, Doerge DR, Fang JL, UpadhyayaP, Lazarus P. Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4. Drug Metab. Dispos. 32 (1), 72-79 (2004). (Pubitemid 38112538)
7. Benoit-Biancamano MO, Adam JP, Bernardo et al. A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. Pharmacogenet. Genomics 19 (12) 945-954 (2009).
8. Mori A, Maruo Y, Iwai M, Sato H, TakeuchiY. UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab. Dispos. 33 (5), 672-675 (2005). (Pubitemid 40593882)
9. Saeki M, Saito Y, Jinno H et al. Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab. Pharmacokinet. 20 (2), 144-151 (2005).
10. Sun DD, Chen GG, Dellinger RR, Duncan KK, Fang JJ, Lazarus PP. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res. 8 (4), R50 (2006).
11. Zhou J, Tracy TS, Remmel RP. Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites. Drug Metab. Dispos. 38 (3), 431-440 (2010).
12. Argikar UA, Remmel RP. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab. Dispos. 37 (1), 229-236 (2009).
13. Hutzler JM, Hauer MJ, Tracy TS. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab. Dispos. 29 (7), 1029-1034 (2001). (Pubitemid 32605919)
14. Kenworthy KE, Clarke SE, Andrews J, Houston JB. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab. Dispos. 29 (12), 1644-1651 (2001). (Pubitemid 33111598)
15. Segel I. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. Wiley Classics Library, NJ, USA (1993).
16. Osborne CK. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339 (22), 1609-1618 (1998). (Pubitemid 28536137)
17. Flockhart D. CYP2D6 genotyping and the pharmacogenetics of tamoxifen. Clin. Adv. Hematol. Oncol. 6 (7), 493-494 (2008).
18. Kaku T, Ogura K, Nishiyama T, Ohnuma T, Muro K, Hiratsuka A. Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem. Pharmacol. 67 (11), 2093-2102 (2004). (Pubitemid 38595490)
19. Wiener D, Fang JL, Dossett N, Lazarus P. Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone glucuronidation phenotype in human liver microsomes. Cancer Res. 64 (3), 1190-1196 (2004). (Pubitemid 38176928)
20. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin. Pharmacol. Ther. 42 (5), 535-541 (1987). (Pubitemid 18002171)
21. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO. Invitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab. Dispos. 34 (6), 1055-1062 (2006). (Pubitemid 43763765)
22. Argikar UA, Remmel RP. Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica 39 (5), 355-363 (2009).
23. Gulcebi IOM, Ozkaynakci A, Ozkara C, Gulhan R, Onat F. Plasma lamotrigine levels of patients with polymorphic UGT1A4 enzymes. Epilepsia 51 (Suppl. 4), 229 (2010).